Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Lee Jackson | Mar 9, 2018 at 10:05 AM EST

5 Top Jefferies Health Care Picks Have Big-Time Potential

These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios.…

Chris Lange | Feb 28, 2018 at 9:15 AM EST

Major Biotechs Continue to See a Rising Tide of Short Interest

The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech…

Trey Thoelcke | Feb 23, 2018 at 10:20 AM EST

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will…

Jon C. Ogg | Feb 22, 2018 at 2:52 PM EST

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.

Chris Lange | Feb 22, 2018 at 10:20 AM EST

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into…

Lee Jackson | Feb 14, 2018 at 8:10 AM EST

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time…

Chris Lange | Feb 12, 2018 at 9:15 AM EST

Major Biotechs See Rising Tide of Short Interest

The January 31 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | Feb 8, 2018 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp, Zynga and More

The top analyst upgrades, downgrades and other research calls from Thursday include Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn,…

Chris Lange | Feb 4, 2018 at 10:25 AM EST

Disney, Tesla, Twitter and More Earnings Coming This Week

24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report…

Chris Lange | Feb 3, 2018 at 8:50 AM EST

Major Biopharma Catalysts on February’s FDA Calendar

24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food…

Jon C. Ogg | Jan 30, 2018 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: Abbott Labs, Alphabet, Amazon, GE, Gilead, Intel, Seagate, US Steel and Many More

The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Alphabet, Amazon.com, General Electric, Gilead Sciences,…

Chris Lange | Jan 29, 2018 at 4:08 PM EST

Monday’s Biggest Winners and Losers in the S&P 500

Monday was a down day for the U.S. markets. Although the markets have been pushing new highs recently, today was…

Chris Lange | Jan 27, 2018 at 9:20 AM EST

Top Stocks to Look For in February’s FDA Calendar

Johnson &; Johnson, Gilead Sciences and Amicus Therapeutics are among companies expecting clinical trial and FDA updates in February.

Jon C. Ogg | Jan 26, 2018 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead, Intel, Starbucks, Yamana Gold and More

The top analyst upgrades, downgrades and other research calls from Friday include Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead Sciences,…

Chris Lange | Jan 25, 2018 at 10:05 AM EST

Short Sellers Raise the Stakes in Major Biotechs

The January 12 short interest data have been compared with the previous report, and short interest moves in the selected…

1 … 16 17 18 19 20 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

5 Top Jefferies Health Care Picks Have Big-Time Potential

Major Biotechs Continue to See a Rising Tide of Short Interest

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

Major Biotechs See Rising Tide of Short Interest

Top Analyst Upgrades and Downgrades: Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp, Zynga and More

Disney, Tesla, Twitter and More Earnings Coming This Week

Major Biopharma Catalysts on February’s FDA Calendar

Top Analyst Upgrades and Downgrades: Abbott Labs, Alphabet, Amazon, GE, Gilead, Intel, Seagate, US Steel and Many More

Monday’s Biggest Winners and Losers in the S&P 500

Top Stocks to Look For in February’s FDA Calendar

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead, Intel, Starbucks, Yamana Gold and More

Short Sellers Raise the Stakes in Major Biotechs

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Gilead Sciences : GILD

All Gilead Sciences Articles

5 Top Jefferies Health Care Picks Have Big-Time Potential

Major Biotechs Continue to See a Rising Tide of Short Interest

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

Major Biotechs See Rising Tide of Short Interest

Top Analyst Upgrades and Downgrades: Apple, GE, Gilead, Humana, Oasis Petroleum, Sprint, Wynn, Yelp, Zynga and More

Disney, Tesla, Twitter and More Earnings Coming This Week

Major Biopharma Catalysts on February’s FDA Calendar

Top Analyst Upgrades and Downgrades: Abbott Labs, Alphabet, Amazon, GE, Gilead, Intel, Seagate, US Steel and Many More

Monday’s Biggest Winners and Losers in the S&P 500

Top Stocks to Look For in February’s FDA Calendar

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Caterpillar, FirstEnergy, Gilead, Intel, Starbucks, Yamana Gold and More

Short Sellers Raise the Stakes in Major Biotechs

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do